



Cite this: *RSC Adv.*, 2025, 15, 35635

A practical synthesis of enantiopure *syn*- β -amino- α -hydroxy acids from α -amino acids with application in the formal syntheses of L-TFB-TBOA and (S)-vigabatrin

Bohua Long,^a Peng Zhang,^{ab} Mengmeng Jiang,^{ab} Pengfei Guo,^{ab} Xuanluan Chen,^{ab} Shunlei Shang^{*c} and Zhengzhi Wu^{*ab}

Received 1st August 2025
Accepted 21st September 2025

DOI: 10.1039/d5ra05586e

rsc.li/rsc-advances

Enantiopure *syn*- β -amino- α -hydroxy acids have been synthesized from α -amino acids in a multi-step procedure that exhibits a high level of stereoselectivity and good overall yields. A stepwise oxidation of the terminal olefin to a carboxylic acid delivered an essentially quantitative yield *via* a cleaner process relative to the conventional one-pot oxidation. The practical value of this transformation has been demonstrated in the formal synthesis of L-TFB-TBOA and (S)-vigabatrin.


Syn- β -amino- α -hydroxy acid fragments are present in numerous biologically active molecules, drugs and natural products, exhibiting diverse biological activities. For example, Taxol and Docetaxel have significant activity in breast, non-small-cell lung, ovarian and head and neck cancers.¹ The analogs, ABT-271 and BMS-275183, showed superior activities compared to Taxol in tumor cell line cytotoxicity assays and *in vivo* tests.² Moreover, natural active peptides, such as Probestin,³ Microginin,⁴ Amastatin,⁵ Rakicidin A⁶ and KRI1314 (ref. 7) have demonstrated significant therapeutic potential as protease inhibitors, a new hypoxia-selective cytotoxin and an orally active renin inhibitor (Scheme 1).

Oxidation of the corresponding α -hydroxy amide generates the α -keto amide in high yield^{8,9} (Scheme 2). The α -ketoamide moiety is found in many drugs and natural products, such as the HCV NS3/4 A protease inhibitor Telaprevir,¹⁰ potent protease inhibitors cyclotheonamides A-B^{11,12} and cyclotheonellazoles A-C.¹³ The α -ketoamide is a peculiarly reactive ambident proelectrophile and pronucleophile moiety. It has been widely utilized by medicinal chemists to develop compounds with favorable biological activities, low toxicity, and promising pharmacokinetic (PK) and drug-like properties with respect to highly complex biological targets.¹⁴

All the *syn*- β -amino- α -hydroxy acid are not readily accessible in an enantiomerically pure form. A method that is capable of rapidly and efficiently producing *syn*- β -amino- α -hydroxy acid

with high stereoselectivity warrants comprehensive exploratory work.

Current methods face several limitations. The most widely used procedure based on the conversion of natural α -amino acids is illustrated in Scheme 3. The protected aldehydes are treated with hazardous NaCN¹⁵ or KCN¹⁶ or ACH^{9,17} to give cyanohydrin intermediates in essentially quantitative yields, with subsequent heating under reflux in aqueous HCl to obtain a *ca.* 1:1 mixture of *syn*- and *anti*-diastereomers.




Scheme 1 Representative bioactive molecules containing the *syn*- β -amino- α -hydroxy acid moiety.

^aThe First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China. E-mail: bhleng121@163.com; szwz001@163.com



^bShenzhen Institute of Geriatric Medicine, Shenzhen, 518035, China

^cDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, 100029, China. E-mail: 18810568600@163.com






Scheme 2 Synthesis of α-keto amide from β-amino-α-hydroxy acid.

Scheme 3 Cyanation reaction for the synthesis of *syn*-β-amino-α-hydroxy acid.Scheme 4 Sharpless reaction for the synthesis of *syn*-β-amino-α-hydroxy acid.

Chiral reagent-controlled synthetic methods, such as selective opening of a chiral epoxide¹⁸ and asymmetric amino-hydroxylation,¹⁹ have been employed as shown in Scheme 4. However, when applied to the alkyl acrylate, these methods deliver poor regioselectivity and stereoselectivity.¹⁹

Naturally occurring α-amino acids have been widely used as chiral building blocks in organic synthesis. As shown in Scheme 5, L-norvaline **1** was selected as the starting material, which was subjected to esterification, Boc protection, and LiAlH₄ reduction. The target α-amino alcohol **2** was oxidized to the corresponding α-amino aldehyde **3** via 2-iodoxybenzoic acid (IBX)-mediated oxidation in quantitative yield with no observed racemization at the stereogenic center.

Following a simple workup, vinylmagnesium bromide (2.5 equiv.) was added to a DCM solution of the aldehyde at 0 °C, resulting in an inseparable mixture of the target *syn*-amino alcohol **4** as the major product and *anti*-alcohol **4'**. The *syn*



Scheme 5 Synthesis of (2R,3S)-3-amino-2-hydroxyhexanoic acid (**8**). (a) SOCl₂, MeOH, reflux, 2 h; (b) Boc₂O, NaHCO₃, THF/H₂O, rt, 10 h; (c) LiAlH₄, THF, rt, 2 h; (d) IBX, MeCN, reflux, 1 h; (e) vinylmagnesium bromide, DCM, 0 °C, 30 min; (f) DMP, *p*-TsOH, DCM, 0 °C, 30 min; (g) K₂OsO₄·2H₂O, NMO, Me₂CO/H₂O, rt, 15 h, then NaIO₄, rt, 1.5 h; (h) 1 M KMnO₄, *t*-BuOH, aq. NaH₂PO₄, rt, 0.5 h; (i) 6 N HCl, reflux, 2 h.

diastereomer **4** can be fully converted into the corresponding *trans*-oxazolidine **5** by treatment with 2,2-dimethoxypropane and a catalytic amount of *p*-toluenesulfonic acid in DCM at 0 °C for 30 min. Under these conditions, the *cis*-oxazolidine **5'** was not formed due to torsional strain. After quenching with excess Et₃N, the mixture was purified by flash chromatography to afford the *trans*-oxazolidine **5** as a mixture of rotamers in 60% yield over two steps.


Following the synthesis of the oxazolidine **5**, the complete and efficient conversion of the allyl moiety into the carboxylic acid **7** was investigated. The use of a one-pot oxidative cleavage procedure, such as the Sharpless NaIO₄/RuCl₃ method^{20,21} or Lemieux-von Rudloff oxidation²² did not result in the clean production of acid **7** (Table 1). An increase in reaction scale resulted in complex product formation.

A stepwise synthesis route was considered where the terminal alkene in **5** underwent dihydroxylation with NMO/K₂-OsO₄·2H₂O (as catalyst) under standard Upjohn conditions.²³ The required diol was cleaved directly with NaIO₄ to give the corresponding aldehyde **6** in quantitative yield without the need for work-up. The transformation of aldehyde **6** into carboxylic acid **7** was evaluated. Treatment of **6** with NaClO₂ in the presence of NaH₂PO₄ and 2-methyl-2-butene as a scavenger²⁴ gave the required acid **7** in 85% overall yield. Oxidation of aldehyde **6** with KOH/I₂/MeOH system²⁵ generated the corresponding methyl ester **7'** with 80% overall yield under mild conditions. Moreover, aldehyde **6** underwent effective oxidation with KMnO₄ to the corresponding carboxylic acid **7** using a mixture of *t*-BuOH and aqueous NaH₂PO₄ (ref. 26) in essentially quantitative yield (Table 1).



Table 1 Oxidation conditions for the *trans*-oxazolidine **5**

Entry	Oxidation conditions	Result
1	NaIO ₄ /RuCl ₃ , CCl ₄ /MeCN/H ₂ O (one-pot)	(7) Mess
2	NaIO ₄ /RuCl ₃ , EA/MeCN/H ₂ O (one-pot)	(7) Mess
3	NaIO ₄ /KMnO ₄ /NaHCO ₃ , <i>t</i> -BuOH/H ₂ O (one-pot)	(7) Mess
4	NaIO ₄ /KMnO ₄ /NaHCO ₃ , Me ₂ CO/H ₂ O (one-pot)	(7) Mess
5	a, b, c (stepwise)	(7) Clean ca. 85% yield
6	a, b, d (stepwise)	(7') Clean ca. 80% yield
7	a, b, e (stepwise)	(7) Clean ca. 100% yield



Scheme 6 Synthesis of *anti*-*N*-Boc- β -amino- α -hydroxy acid methyl ester (**11**). (a) SOCl₂, MeOH, reflux, 2 h; (b) Boc₂O, NaHCO₃, THF/H₂O, rt, 10 h; (c) *p*-nitrobenzoic acid, DIAD, PPh₃, THF, rt, 2 h; (d) K₂CO₃, MeOH, 0 °C, 20 min.

The subsequent removal of N,O-acetonide under standard conditions, including the use of TsOH, aqueous HCl, aqueous H₂SO₄, and aqueous TFA is challenging. The products formed are complex due to a partial deprotection of **7**. Following extensive experiments, all the protecting groups associated with **7** were fully removed by refluxing with 6 N HCl for 2 h. After a simple workup, the target enantiopure (2*R*,3*S*)-3-amino-2-hydroxyhexanoic acid product **8** was obtained as a hydrochloride salt in 90% overall yield over 3 steps from the starting compound **5**, which has been used as a key intermediate for the synthesis of Telaprevir as reported by Porala.²⁷ As determined by NMR spectra, the reactions take place with a very high stereoselectivity, giving only *syn*- β -amino- α -hydroxy acid **8** with complete retention of the starting configuration at C-2.

Anti- β -amino- α -hydroxy acids have also received considerable attention as crucial components in natural products such as perthamide C¹⁸ and largamide H.²⁸ In order to secure ready access to the desired *anti*- β -amino- α -hydroxy acid, an inversion of the alcohol configuration in the *syn*-product **8** was studied.


Following esterification and Boc-protection, inversion of the α -hydroxy stereocenter in the corresponding compound **9** was achieved using a standard Mitsunobu procedure²⁹ with *p*-nitrobenzoic acid, diisopropyl azodicarboxylate (DIAD) and PPh₃, affording **10** in 85% yield. A subsequent mild saponification was conducted using K₂CO₃ in MeOH to produce *anti*-*N*-Boc- β -amino- α -hydroxy acid methyl ester **11** in 80% yield with complete inversion of the stereochemical configuration of the alcohol starting material determined by NMR spectra (Scheme 6).

The general applicability of these optimal conditions was examined in the preparation of other *syn*- β -amino- α -hydroxy acids from α -amino acids: the results are given in Tables 2 and 3. All the reactions delivered the target products in high overall yield. Details regarding experimental procedures are provided in the SI (SI).

In order to demonstrate the application of the proposed method in terms of "total" synthesis, we have conducted the formal syntheses of the corresponding biologically active molecules. In addition, we derivatized compound **7I** by methylation³⁰ and converting the phenyl moiety *via* oxidative cleavage with NaIO₄/RuCl₃ to the carboxylic acid,³¹ producing the acid **12** in good yield. Following global deprotection with 6 N HCl, *L*-threo-3-hydroxyaspartic acid **13**, which is a potent excitatory amino acid transporter (EAAT) inhibitor and a crucial component of Rakicidin A, was synthesized as the hydrochloride salt in 70% yield over five steps from **5I** (Scheme 7). The production of **13** represents the formal syntheses of *L*-TFB-TBOA as **13** had been used to generate the complex amino acid by Poelarends.³² It should be noted that *L*-TFB-TBOA exhibits nanomolar affinity for EAAT1 and EAAT2 and lacks affinity with respect to glutamate-gated ion channels.

As shown in Scheme 8, dihydroxylation of the olefin in **5k** followed by glycol cleavage with sodium periodate produced the



Table 2 Synthesis of *syn*-β-amino-α-hydroxy acids (**8a–8k**) from α-amino acids (**1a–1k**)

Entry	Starting material (S)-α-amino acid (1a–1k)	<i>trans</i> -Oxazolidine (5a–5k)	<i>syn</i> -β-amino-α-hydroxy acid hydrochloride salt (8a–8k)
1	 <i>L</i> -Isoleucine (1a)	 5a 60% yield from 1a	 8a (2.2 g) 80% yield from 5a
2	 <i>L</i> -Phenylalanine (1b)	 5b 55% yield from 1b	 8b ^a (2.6 g) 78% yield from 5b
3	 <i>L</i> -Valine (1c)	 5c 52% yield from 1c	 8c (2.0 g) 74% yield from 5c
4	 <i>L</i> -Phenylglycine (1d)	 5d 45% yield from 1d	 8d (1.8 g) 76% yield from 5d
5	 <i>L</i> -Cyclohexylalanine (1e)	 5e 45% yield from 1e	 8e ^b (1.5 g) 75% yield from 5e
6	 <i>L</i> - <i>tert</i> -Leucine (1f)	 5f 60% yield from 1f	 8f ^c (2.5 g) 95% yield from 5f
7	 <i>L</i> -Leucine (1g)	 5g 50% yield from 1g	 8g ^d (2.6 g) 95% yield from 5g
8	 <i>L</i> -Alanine (1h)	 5h 45% yield from 1h	 8h (2.0 g) 85% yield from 5h



Table 2 (Contd.)

Entry	Starting material (S)- α -amino acid (1a–1k)	<i>trans</i> -Oxazolidine (5a–5k)	<i>syn</i> - β -amino- α -hydroxy acid hydrochloride salt (8a–8k)
9	 5-Methyl-L-norleucine (1i)	 5i 50% yield from 1i	 8i (1.4 g) 84% yield from 5i
10	 S-2-Aminononanoic acid (1j)	 5j 55% yield from 1j	 8j (1.2 g) 85% yield from 5j
11	 L-Homophe-OH (1k)	 5k 52% yield from 1k	 8k (1.5 g) 85% yield from 5k

^a Key component of Taxol. ^b Key component of KRI-1314. ^c Key component of BMS-275183. ^d Key component of ABT-271 and KRI-1230.

corresponding aldehyde, which was reduced with NaBH₄ to afford the alcohol **14** in 95% yield over three steps. The acetonide group of **14** can be readily deprotected to generate **15** in quantitative yield by treatment with a methanolic solution of *p*-TsoH. The conversion of the **15** diastereomer to (S)-vigabatrin has been reported.^{33,34} Therefore, the sequence presented in this study constitutes a formal synthesis of (S)-vigabatrin, which serves as an irreversible gamma-aminobutyric acid (GABA)-transaminase inhibitor. The S-isomer is pharmacologically active, whereas the R-isomer is inactive.

Conclusions

In summary, we have developed a practical synthetic route to enantiopure *syn*- β -amino- α -hydroxy acid from α -amino acid that exhibits a high level of stereoselectivity. Following the addition of a vinyl Grignard reagent to a *N*-Boc- α -amino aldehyde, kinetic resolution accompanied acetonide formation at 0 °C for 30 min to give the corresponding *trans*-oxazolidine diastereo-selectively in good yield. A dihydroxylation-oxidative cleavage sequence of

the terminal olefin in *trans*-oxazolidine afforded the aldehyde, which underwent side-chain oxidation to deliver the carboxylic acid in very high yield. A final global deprotection in refluxing 6 N hydrochloric acid generated *syn*- β -amino- α -hydroxy acid as the hydrochloride salt. Inversion of the α -hydroxy stereocenter of the *syn*-*N*-Boc- β -amino- α -hydroxy acid methyl ester was completed in a Mitsunobu reaction with subsequent saponification to give the *anti*-*N*-Boc- β -amino- α -hydroxy acid methyl ester in good yield.

The synthesis of L-threo-3-hydroxyaspartic acid **13** and *N*-Boc-aminodiols **15** represents a formal approach to the total synthesis of L-TFB-TBOA and (S)-vigabatrin. The proposed procedure offers a viable alternative to current methods for preparing enantiopure *syn*- β -amino- α -hydroxy acids and represents a viable route in the preparation of a variety of biologically important compounds containing this crucial amino acid moiety. Our strategy represents a simple and scalable process with a low environmental impact. Further work is now in progress.




Table 3 Synthesis of *syn*- β -amino- α -hydroxy acids (**8l–8p**) from α -amino acids (**1l–1p**)

General reaction scheme for the synthesis of **8l-8p** from **1l-1p**:


1l-1p (starting material) $\xrightarrow{\text{a-d}}$ **3l-3p** (intermediate) $\xrightarrow{\text{e-f}}$ **5l-5p** (intermediate) $\xrightarrow{\text{g-h}}$ **7l-7p** (intermediate) $\xrightarrow{\text{i}}$ **8l-8p** (final product).

Yields: **5l-5p** (45-60% yield from **1l-1p**); **8l-8p** (75-95% yield from **5l-5p**).

^a Key component of Amastatin. ^b Key component of Microginin. ^c Key component of Bestatin, Phebestin and Probestin.



Scheme 7 Formal synthesis of L-TFB-TBOA. (a) $K_2OsO_4 \cdot 2H_2O$, NMO, Me_2CO/H_2O , rt, 16 h, then $NaIO_4$, rt, 1.5 h; (b) 1M $KMnO_4$, $t-BuOH$, aq. NaH_2PO_4 , rt, 0.5 h; (c) MeI, K_2CO_3 , Me_2CO , reflux, 3 h; (d) $NaIO_4$, $RuCl_3$, $CCl_4/MeCN/H_2O$, reflux, 3 h; (e) 6 N HCl, reflux, 2 h.



Scheme 8 Formal synthesis of (S)-vigabatrin. (a) $K_2OsO_4 \cdot 2H_2O$, NMO, Me_2CO/H_2O , rt, 14 h, then $NaIO_4$, rt, 1.5 h; (b) $NaBH_4$, MeOH, rt, 1 h; (c) $p-TsOH$, MeOH, rt, 12 h.



Conflicts of interest

There are no conflicts to declare.

Data availability

The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files (SI). Should any raw data files be needed in another format they are available from the corresponding author upon reasonable request. Source data are provided with this paper. Supplementary information is available. See DOI: <https://doi.org/10.1039/d5ra05586e>.

Acknowledgements

We thank Guangdong Provincial Enterprise Joint Fund Project (2022A1515220041), Shenzhen Natural Science Foundation General Project (JCYJ20220530150413029), Shenzhen Key Discipline Layout Project (JCYJ2022081801866014) and The major new drug innovation project of the Ministry of Science and Technology of China (No. 2017ZX09301001) for financial support.

References

- 1 J. Gallego-Jara, G. L. ozano-Terol, R. A. Sola-Martinez, M. Canovas-Diaz, T. Diego Puente and T. de Diego Puente, *Molecules*, 2020, **25**, 5986.
- 2 L. Li, S. A. Thomas, L. L. Klein, C. M. Yeung, C. J. Maring, D. J. Grampovnik, P. A. Lartey and J. J. Plattner, *J. Med. Chem.*, 1994, **37**, 2655–2663.
- 3 G. Pathuri, J. E. Thorpe, B. C. Disch, L. C. Bailey-Downs, M. A. Ihnat and H. Gali, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 3561–3564.
- 4 T. Okino, H. Matsuda, M. Murakami and K. Yamaguchi, *Tetrahedron Lett.*, 1993, **34**, 501–504.
- 5 D. H. Rich, B. J. Moon and S. Harbeson, *J. Med. Chem.*, 1984, **27**, 417–422.
- 6 Y. Yamazaki, S. Kunimoto and D. Ikeda, *Biol. Pharm. Bull.*, 2007, **30**, 261–265.
- 7 Y. Etoh, M. Miyazaki, H. Saitoh and N. Toda, *Jpn. J. Pharmacol.*, 1993, **63**, 109–119.
- 8 Y. Cui, M. Zhang, H. Xu, T. Zhang, S. Zhang, X. Zhao, P. Jiang, J. Li, B. Ye, Y. Sun, M. Wang, Y. Deng, Q. Meng, Y. Liu, Q. Fu, J. Lin, L. Wang and Y. Chen, *J. Med. Chem.*, 2022, **65**, 2971–2987.
- 9 B. Long, L. Pu, Z. Liu, X. Zeng and Z. Wu, *Org. Biomol. Chem.*, 2023, **21**, 3531–3536.
- 10 O. M. Klivanov, S. H. Williams, L. S. Smith, J. L. Olin and S. B. Vickery, *Pharmacotherapy*, 2011, **31**, 951–974.
- 11 N. Fusetani and S. Matsunaga, *J. Am. Chem. Soc.*, 1990, **112**, 7053–7054.
- 12 Y. Murakami, M. Takei, K. Shindo, C. Kitazume, J. Tanaka, T. Higa and H. Fukamachi, *J. Nat. Prod.*, 1998, **61**, 667–670.
- 13 M. Issac, M. Akin, A. Gauvin-Bialecki, N. D. Voogd, A. Ledoux, M. Frederich, Y. Kashman and S. Carmeli, *J. Nat. Prod.*, 2017, **80**, 1110–1116.
- 14 M. Robello, E. Barresi, E. Baglini, S. Salerno, S. Taliani and F. D. Settimo, *J. Med. Chem.*, 2021, **64**, 3508–3545.
- 15 M. Kohr, C. Walt, J. Dastbaz, R. Müller and U. Kazmaier, *Org. Biomol. Chem.*, 2022, **20**, 9609–9612.
- 16 E. P. Johnson, M. P. Hubieki, A. P. Combs and C. A. Teleha, *Synthesis*, 2011, 4023–4026.
- 17 M. Göhl, L. Zhang, H. El Kilani, X. Sun, K. Zhang, M. Brönstrup and R. Hilgenfeld, *Molecules*, 2022, **27**, 4292.
- 18 V. Sepe, M. V. D'Auria, G. Bifulco, R. Ummarino and A. Zampella, *Tetrahedron*, 2010, **66**, 7520–7526.
- 19 G. Li, H. T. Chang and K. B. Sharpless, *Angew. Chem., Int. Ed. Engl.*, 1996, **35**, 451–454.
- 20 M. Commandeur, C. Commandeur and J. Cossy, *Org. Lett.*, 2011, **13**, 6018–6021.
- 21 F. Zimmermann, E. Meux, J. L. Mieloszynski, J. M. Lecuire and N. Oget, *Tetrahedron Lett.*, 2005, **46**, 3201–3203.
- 22 A. Expósito, M. Fernández-Suárez, T. Iglesias, L. Munoz and R. Rigüera, *J. Org. Chem.*, 2001, **66**, 4206–4213.
- 23 V. VanRheenen, R. C. Kelly and D. Y. Cha, *Tetrahedron Lett.*, 1976, **17**, 1973–1976.
- 24 B. S. Bal, W. E. Childers Jr and H. W. Pinnick, *Tetrahedron*, 1981, **37**, 2091–2096.
- 25 S. Yamada, D. Morizono and K. Yamamoto, *Tetrahedron Lett.*, 1992, **33**, 4329–4332.
- 26 A. Abiko, J. C. Roberts, T. Takemasa and S. Masamune, *Tetrahedron Lett.*, 1986, **27**, 4537–4540.
- 27 S. Porala, J. R. Yerrabelly, V. R. Kasireddy, H. Yerrabelly, V. R. Ghajala and P. Rebelli, *ChemistrySelect*, 2019, **4**, 9523–9528.
- 28 A. Plaza and C. A. Bewley, *J. Org. Chem.*, 2006, **71**, 6898–6907.
- 29 K. C. K. Swamy, N. N. B. Kumar, E. Balaraman and K. V. P. P. Kumar, *Chem. Rev.*, 2009, **109**, 2551–2651.
- 30 Y. Seo, H. Kim, D. W. Chae and Y. G. Kim, *Tetrahedron: Asymmetry*, 2014, **25**, 625–631.
- 31 T. Novak, Z. Tan, B. Liang and E. Negishi, *J. Am. Chem. Soc.*, 2005, **127**, 2838–2839.
- 32 H. Fu, S. H. H. Younes, M. Saifuddin, P. G. Tepper, J. Zhang, E. Keller, A. Heeres, W. Szymanski and G. J. Poelarends, *Org. Biomol. Chem.*, 2017, **15**, 2341–2344.
- 33 M. Alcón, M. Poch, A. Moyano, M. A. Pericàs and A. Riera, *Tetrahedron: Asymmetry*, 1997, **8**, 2967–2974.
- 34 C. Dagoneau, A. Tomassini, J. N. Denis and Y. Vallée, *Synthesis*, 2001, 150–154.